BSX Stock Recent News

The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Boston Scientific's fourth-quarter 2024 performance reflects the strength of its core franchises.

Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago.

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

MARLBOROUGH, Mass. , Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period.

Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

Evaluate the expected performance of Boston Scientific (BSX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.

Boston Scientific is expected to have registered strong growth in the Asia Pacific in the fourth quarter, led by strength in China and Japan.